Virax biolabs group ltd VRAX.US Overview Analysis
VRAX AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
VRAX Current Performance
1.98%
Virax biolabs group ltd
0.23%
Avg of Sector
0.43%
S&P500
Top 10 High Relevance to VRAX
- INM Inmed pharmaceuticals incValue 2Trend 3Swing Trading 4Whale Interest 1Dividend 1See more
VRAX Profile
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.